In line with its continued mission to supply branded generics to emerging markets, such as Africa and Latin America, AstraZeneca has entered into yet another agreement with an Indian generics firm.
AstraZeneca expands its generics business with Indian agreements
Home/Pharma News
|
Posted 01/10/2010
0
Post your comment

The latest licensing and supply agreement is with Indian generics firm Intas Pharmaceuticals. The agreement will see the Ahmedabad-based firm provide the Anglo-Swedish drugmaker with injectable and oral cancer drugs to be sold under AstraZeneca's name.
This agreement comes hot on the heels of two other deals with Indian generics’ manufacturers made during 2010.
An agreement with Hyderabad-based Aurobindo Pharma was set up at the beginning of September 2010 covering licensing and supply of a broad range of products in therapeutic areas such as anti-infectives, cardiovascular system and central nervous system.
Earlier this year, AstraZeneca also signed a long term supply deal with Ahmedabad's Torrent Pharma for 18 products in nine countries, once again to be sold under AstraZeneca's name.
Head of Branded Generics Operations at AstraZeneca, Mr Kaushik Banerjee, commented on the agreements, saying that “these agreements will enable us to extend the range of branded medicines we are able to offer patients in emerging markets, where we see continued opportunities to grow our business”.
References
Business Standard. Intas Pharma links supply deal with AstraZeneca. 21 September 2010.
Aurobindo Pharma. Latest News. Aurobindo Pharma announces Licensing and Supply Agreements with AstraZeneca for Supply of Finished Dosage Products to Emerging Markets. 6 September 2010.
Torrent Pharmaceuticals Limited. Research Collaborations. Research Alliance with AstraZeneca [monograph on internet] c2003 [Accessed 2010 September 21].
AstraZeneca. Press Releases. AstraZeneca Extends Branded Generics Capability With Torrent Agreement. 11 March 2010.
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment